In sepsis, trauma and major surgery, where an explicit physiological insult leads to a significant systemic inflammatory response, the acute evolution of biomarkers have been delineated. In these settings, Interleukin (IL) -6 and TNF-α are often the first pro-inflammatory markers to rise, stimulating production of acute phase proteins followed by peaks in anti-inflammatory markers. Patients undergoing SPKT as a result of diabetic complications already have an inflammatory phenotype as a result of uraemia and glycaemia. How this inflammatory response is affected further by the trauma of major transplant surgery and how this may impact on graft survival is unknown, despite the recognised pro-inflammatory cytokines' detrimental effects on islet cell function.
Introduction
In sepsis, trauma and major surgery, where an explicit physiological insult leads to a significant systemic inflammatory response, the acute temporal biomarker expression patterns of acute phase proteins have been described [1] [2] [3] [4] [5] [6] . In these conditions, Interleukin (IL) -6 and TNF-α appear to be the first pro-inflammatory markers to rise, triggering the production of acute phase proteins, leading to peaks in anti-inflammatory markers [5] . Biomarkers are now used to improve specificity for risk stratification and predict outcomes at an early stage of the disease process [7] [8] [9] , estimate extent of tissue damage [6, 10, 11] and provide targets for novel pharmacological therapies [12] [13] [14] . In chronic diseases such as insulin dependent diabetes mellitus (IDDM) and endstage renal failure (ESRF), specific pro-inflammatory markers (IL -4, -6, -8, TNF-α) are persistently raised [14, 15] , leading to higher cardiovascular risk in this cohort [16] .
Simultaneous pancreas and kidney transplantation (SPKT) recipients suffer with an exacerbated inflammatory phenotype as a result of uraemia and glycaemia, which has contributed to multi-system morbidity, end-organ failure, while and at transplantation, they undergo high-risk surgery, which further aggravates the inflammatory response. This reaction is clinically akin to sepsis and major trauma, and provides the impetus for current guidelines to recommend a more detailed surveillance. There is an urgent and unmet need to identify and validate accurate biomarkers for the detection of complications to improve quality of life for the patients and reduce costs for health care providers, while maintaining or improving current outcomes. Explicit clinical factors, which include a prolonged cold ischaemic time (CIT), recipient BMI greater than 30 kg/m 2 [17] , recipient age greater than 45 years [18] and donor age greater than 40-45 [19, 20] have all been identified as clinical markers correlating to poor outcomes. However, relevant biological profiling in this clinical context has not been investigated and the temporal evolution and interactions of peri-operative inflammatory markers (IMs) have not been characterised.
In solid-organ transplantation, biomarkers have been investigated in relation to donation after brainstem death (DBD), the impact of ischaemia-reperfusion-injury (IRI) and in rejection [21] [22] [23] . High levels of IL-1, -2, -4, -10 and TNF-α in the peri-operative period correlate with reduced long-term graft survival and increased rates of rejection. During islet cell transplantation, β-cells produce pro-inflammatory cytokines leading to β-cell dysfunction, graft toxicity and islet-cell death [24] [25] [26] [27] . This has led to the introduction of anti-TNF-α agents being used as part of induction immunosuppression in some islet transplant centres, with evidence suggesting improved rates of graft survival [28] [29] [30] . In the setting of pancreatitis, the most widely available stressor model affecting the pancreas, raised levels of inflammatory cytokines (IL-6, IL-8, TNF-α and IL-10) have been observed and aid in prognosis prediction [7] . We propose that a measure of a panel of independent complementary biomarkers, including the markers with classic prognostic properties, together with novel inflammatory and endocrine markers may provide a more accurate prediction of outcome, compared with a few individual markers, thus improving risk stratification and clinical management of patients following SPKT.
Additionally, measuring both tissue and circulating biomarkers add valuable novel information to the study for diagnosing further surgical complications. Human adipose tissue is a metabolically active organ. The function and metabolic activity of the fat varies, depending on the location within the body [31] , but higher levels of obesity correlate with higher levels of circulating IMs [32] leading to increased cardiovascular risk in the obese patient.
Within the abdomen, the omentum is an apron of fat, which like other deposits of fat, is a physiologically and metabolically active organ [33] . In surgery, it is known as the "abdominal policeman" as it is often found to encase areas of intra-abdominal inflammation and infection. The omentum is also involved in the formation of peritoneal adhesions and the production of growth factors and cytokines [33, 34] . It reacts to a localised inflammatory insult via macrophage production of IMs (TNF-α, Resistin, plasminogen activator inhibitor-1 (PAI-1) and multiple interleukins [35] ) resulting in a systemic effect [36] . This role has been outlined in cases of intra-abdominal sepsis, but minimal evidence exists as to the role of the omentum in instigating a systemic inflammatory reaction in response to an elective intra-abdominal procedure [37] .
In SPKT, assumptions are also made regarding the production of endocrine markers by the allograft pancreas. Given that serum blood sugar levels tend to fall within the first hour post-pancreatic perfusion, and demonstrable primary pancreatic graft dysfunction is exceptionally rare, it is assumed that endocrine function is instantaneous and uniform, with the distinction between "impaired" or "delayed" graft function difficult to characterize.
Therefore, this study aimed to determine the temporal evolution of biomarkers in the peri-operative period following SPKT, assess the inflammatory response of omentum in relation to elective major surgery and establish a correlation of serum biomarkers to clinical outcome.
Methods

Study centre
The study was undertaken at The Central Manchester University Hospitals NHS Trust and The University of Manchester. Appropriate ethical and Research and Development approvals were obtained. Recipient serum and omental biopsies were taken prospectively from SPKT recipients between November 2011 and March 2014.
Study design
This study was designed to:
1. Delineate the temporal evolution of IMs (IL-6 and -10, TNF-α, Creactive protein (CRP), White Cell Count (WCC) and Amylase) and endocrine markers (C-peptide, insulin, glucagon and resistin) in the perioperative period following SPKT; 2. Evaluate specific factors which may affect the levels of inflammatory and endocrine markers; 3. Correlate biomarker levels with clinical outcomes.
All adult SPKT recipients were eligible for inclusion in the study. Serum samples were taken and processed for analysis on eight occasions in the peri-operative period (pre-operatively, immediately prior pancreas perfusion, 30 min post pancreas perfusion and at 6, 12, 24, 48 and 72 h post-transplantation) [38] . Two omental biopsies were taken intraoperatively, firstly on entering the abdomen and secondly prior to closing the abdomen. Specimens were processed in an automated processor and wax embedded for subsequent immunohistochemical analysis.
Serum sample analysis
Serum CRP, Amylase and WCC were measured prospectively by the biochemistry and haematology departments at the investigating unit. IL-6, IL-10 and TNF-α, were all measured in serum using ELISA development kits from R&D Systems (Abingdon, UK). Minimum detection limits were 1 pg/ml, 5 pg/ml and 2 pg/ml respectively. Readings below these minimal levels were considered as 0 for analysis. Insulin, C-peptide, glucagon and resistin were measured in bulk using a bioplex micro-array multi-bead based system (BioRad Life Science Group, USA). Minimum detection limits were 1.0 pg/ml, 14.5 pg/ml, 4.9 pg/ml and 1.3 pg/ml for insulin, C-peptide, glucagon, and resistin respectively. Beyond this level, the software imputes likely doses, by extrapolating the calibration curves.
Omental biopsy analysis
Two omental biopsies were taken intra-operatively by the operating surgeon, firstly on entering the abdomen and secondly prior to closing the abdomen. Samples were fixed in 4% formaldehyde then processed and wax embedded in an automated tissue processor. 7 µm sections were cut, mounted on positively charged slides (Superfrost®) and H&E staining was performed. Sections were cut and mounted as above, then dewaxed and rehydrated. Antigen retrieval was performed in heated 1 mM citric acid (pH6) and non-specific antigen binding was blocked in 10% goat serum in phosphate buffer solution (PBS). Sections were exposed to either anti-CD68 antibody (M1 macrophages, Dako) or anti-CD206 antibody (M2 macrophages, Abcam), diluted 1:100 in 1% goat serum in PBS, then detected using biotinlylated secondary antibody (Vector Labs) and the ABC system (Vector Labs). Counterstaining was performed with Mayer's haematoxylin (Fisher Scientific) and sections were dehydrated then mounted in DPX reagent (Sigma). Slides were visualised on a Zeiss Axio Scope light microscope and quantified using ImageJ analysis software.
Patient characteristics and clinical data
Patient, donor, organ, operative and outcome data were recorded to assess for potential confounders and factors affecting either the inflammatory or endocrine marker levels in the post-operative period, as well as to correlate biomarker levels with clinical outcomes. In addition, Multiple Organ Dysfunction Score (MODS) [39] and Post-Operative Morbidity Survey Score (POMS) were calculated and recorded for correlation to peak biomarker levels.
Transplant protocol
Induction immunosuppression was with alemtuzumab (Campath®, Sanofi, Paris, France), 30 mg subcutaneous injection at induction of anaesthesia (repeated at 24 h post-operatively) and methylprednisolone (Solu-Medrone®, Pfizer, New York). Transplant protocol, maintenance immunosuppression and standard post-operative care were as previously described [40] .
Statistical analysis
Statistical analyses were carried out using SPSS (IBM SPSS Statistics 20, Armonk, New York). Continuous data are presented as mean (Standard Deviation) where normally distributed, or median (Interquartile range, IQR, 25th-75th percentile) if skewed. The temporal evolution of biomarkers in the peri-operative period have been graphically presented (95% C.I.) with variation in individual biomarker levels with time analysed using Analysis of Variance (ANOVA) testing with Bonferroni Correction (p < .05 considered significant). Correlations of individual IMs were also made using Pearson correlation (p and r values presented). Univariate analyses and multiple regression analysis were carried out to assess the impact of potential confounders (DBD/Donor after cardiac death (DCD) status, further surgery within 72 h of SPKT and pancreas CIT) on biomarker levels at specific timepoints. Scatter plots were drawn to evaluate the relationship between biomarker levels and CIT. p < .05 for each independent variable was considered significant. Peak biomarker levels of IL-6, IL-10, Amylase and WCC were correlated to clinical outcomes (number of post-operative complications, length of hospital stay, length of critical care unit stay, days to mobilisation out of bed, time to tolerating normal diet, 72 h MODS and days 5, 7 and 10 POMS) using Spearman Correlation. In the case of CRP, which did not reach peak within 72 h, levels at 24, 48 and 72 h were correlated with the clinical outcomes. p < .05 was considered significant.
Results
Patient demographics
There were 69 recipients of SPKTs during the recruitment period. Of these, complete serum and omental samples of 46 recipients were analysed. Baseline recipient, donor and operative variables are detailed in Table 1 . In uni-variate analysis, no potential confounder had a significant effect upon endocrine marker levels within the first 72 h post-operatively (p > .05) Therefore, multivariate analysis with further variables was not conducted.
Inflammatory markers
Levels of IL-6 (n = 45, one outlier excluded, Fig. 2a ) increased rapidly at the start of surgery, peaking at 30 min post-pancreas perfusion (92.27 pg/ml (149.44), p = .001, when compared to pre-perfusion levels, 53.94 pg/ml (134.43) and tended to decrease in concentration over the following 72 h post-transplantation.
Levels of IL-10 ( Fig. 2b) began to increase prior to pancreas perfusion, but peaked significantly at six hours post-operatively (p < .001) when compared to pre-operative levels (2.89 pg/ml (6.70) and 89.24 pg/ml (89.66) respectively). Following this peak, levels fell significantly over the following six hours to 37.04 pg/ml (37.39, p = .008) and continued to decline, reaching baseline levels at 72 h (2.89 pg/ml (6.70) at baseline and 9.70 pg/ml (20.76) at 72 h, p = .819). Levels of TNF-α (Fig. 2c) increased after start of surgery, before returning to baseline values within 12 h of surgery, but none of these temporal changes were significant at any time point (p = .788). Levels of WCC (Fig. 2d) [8] [9] [10] [11] [12] [13] [14] [15] [16] of results at that time-point. CRP levels (Fig. 2e) When comparing levels of IMs at corresponding time-points there were no significant correlations between IM levels (p > .05). However, when correlations were made between peak IM levels, the data became highly significant between TNF-α and IL-6 (p < .001, r = 0.556) and TNF-α and IL-10 (p = .001, r = 0.420).
In uni-variate analysis, no potential confounder had a significant effect upon IM levels at any point within the first 72 h post-operatively (p > .05). Therefore, multivariate analysis with these variables was not conducted.
Inflammatory markers in omentum
Analysis of intra-operative omental biopsies indicate acutely raised levels of inflammatory macrophages, M1 (CD68+) and protective M2 (CD206+) macrophages, when comparing the biopsies at the start and the end of surgery (p = .003 and p < .001 respectively) (Fig. 3) . Representative patient samples highlighting CD68+ and CD206+ staining validates the quantitative analysis of these findings (Fig. 3) .
Biomarker relationship with cold ischaemic time
Endocrine markers
In a simple linear regression model, C-peptide, insulin and glucagon levels were significantly inversely correlated with increasing CIT at every time point, up to 72 h post-SPKT. Fig. 4a -c highlight the correlations between C-peptide, insulin and glucagon respectively, with CIT at 72 h. Furthermore, when assessed as a multiple regression model, CIT continues to exert a significant influence on insulin, C-peptide and glucagon levels within the first 72 h (Table 2) , but not at every timepoint, as suggested by the simple linear regression model.
Inflammatory markers
In a multiple regression model, increasing CIT did not significantly influence IL-6, IL-10, TNF-α, Amylase and CRP, at any time-point within the first 72 h post-transplantation (p > .05). CIT did significantly influence WCC at 12 h post-SPKT (mean level 11.77 × 10 9 /L (3.42), p = .021, r = −0.353).
Correlation of peak inflammatory marker levels with clinical outcome
Clinical outcomes for this patient cohort are outlined in Table 3 . CRP levels at 24, 48 and 72 h post-operatively (91.19 mg/L (38.03), 132.14 mg/L (84.73), 164.23 mg/L (115.18) respectively) correlated significantly with POMS on post-operative days 5, 7 and 10, the time taken for the patient to mobilise from the bed and the total number of post-operative complications suffered by the recipient during their inpatient stay (Table 4) . However, peak levels of IL-6, IL-10, WCC and Amylase did not correlate with any clinically assessed outcome (p > .05).
Discussion
This study has demonstrated the inflammatory and endocrine marker profiles related to biomarker patterns after SPKT. In our patient group, we have defined the temporal evolution of serum IM profiles (IL-6, IL-10, TNF-α, WCC, CRP and Amylase) and serum endocrine marker profiles (insulin, C-peptide, glucagon and resistin) up to 72 h post-SPKT. Concurrently, this study has shown a significant rise in localised 
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omental expression of CD68+ and CD206+ macrophages intra-operatively. In addition, we have demonstrated the significant negative impact of prolonged CIT on pancreatic endocrine function and finally we have presented data suggesting that consistently raised levels of post-operative CRP may be a valuable biomarker of morbidity following SPKT.
Biomarker profiles are associated with specific outcomes in a range of clinical settings [6] [7] [8] [9] [10] [11] . This is the first study to show similar profiles of IM levels in the context of SPKT. Our paper demonstrates an early rise in TNF-α, despite the administration of pre-operative anti-inflammatory therapies, peaking prior to pancreas perfusion, suggesting the biggest systemic inflammatory insult during SPKT is not at the time of graft reperfusion, and unlikely to be significantly related to IRI (as is commonly perceived). Instead, the most notable pro-inflammatory insult may be surgical trauma. The successive peaks in IL-6 and IL-10 that follow, are consistent with previously published data regarding the chronological evolution of IMs, following major physiological stressor events [25, 41, 42] . Our data also suggest a strong correlation between the peaks in TNF-α and IL-6 and IL-10, confirming a relationship between these three biomarkers. Of note, all three cytokines return to baseline within 72 h of surgery, despite the clinically observed persistent pro-inflammatory state, suggesting other factors should be monitored for an improved prognosis of outcome.
Since macrophages are known to secrete CRP, it seems likely that CRP and indeed other biomarkers could be secreted locally into the circulation by the presence of omentum macrophages. Since these cells are classified into two broad classes based on their secretion profile and cell surface markers; analysis of the omental biopsies enabled us to identify the increased presence of both M1 (classical) and M2 (alternative) macrophages. The data confirm a significant increase in infiltration of intra-abdominal phenotypic pro-inflammatory CD68+, M1 sub-type together with an increase in the alternative CD206+, M2 macrophage sub-set, which is associated with anti-inflammatory cytokine production. Whether this is a response to the immuno-suppression or simply a reparative mechanism due to surgical trauma and whether the ratio of these two phenotypes could play a role in outcome remains to be elucidated. The data confirm the simultaneous initiation of a localised and speedy inflammatory response to surgery and a correlation of increased CRP with macrophage infiltration into the omentum. Our data also show rapid rises in insulin, C-peptide and glucagon levels immediately after pancreas allograft reperfusion which plateau within 24 h post-surgery. Naziruddin et al. [43] postulate that high levels of circulating C-peptide immediately after islet transplantation, rather than being a sign of immediate function, may be a sign of islet cell damage, perhaps due to the instant blood-mediated inflammatory reaction described in islet cell transplantation [44] . Given our results, we postulate that in solid-organ PT, the opposite is true. The strong correlations of insulin, C-peptide and glucagon with CIT suggest, that CIT negatively impacts on pancreatic endocrine function, and rather than higher levels of C-peptide being a result of islet cell damage, we propose that higher levels detected with shorter CIT are likely to be due to improved islet cell function in solid-organ PT. Pancreatic CIT has been strongly linked to recipient morbidity previously [45] , but here we present biochemical evidence of the detrimental effect of prolonged CIT on pancreatic endocrine function. This variation in endocrine function observed in relation to CIT, highlights the presence of reduced graft function in PT attributable to a defined and modifiable variable, a previously unreported phenomenon. This finding should encourage the implementation of specific, islet- protective, peri-operative strategies in grafts with prolonged CIT. In addition, our data support previous suggestions by Barton et al. [46] for the use of specific anti-inflammatory induction of immunosuppressive factors to help reduce early graft dysfunction and improve long-term graft survival, given; firstly the inflammatory load on the recipient at the time of pancreas perfusion, and secondly, the known deleterious effects of pro-inflammatory cytokines on islet function and survival in isolated islet cell transplantation [24] [25] [26] [27] . This course of therapy has been used successfully in animal models [47] and in clinical islet transplantation [25] and should perhaps be utilised in PT.
Monitoring biomarkers in a disease process provides the opportunity to modify current treatment strategies, and/or to target the negative clinical processes modulated by specific biomarkers, thus delivering a positive influence on patient outcome.
A second advantage of defining biomarkers and delineating their profiles in a pathological process is the ability to monitor the disease or intervention progression and predict outcome. Serum is readily available and the ability to correlate serological markers to patient outcome is of tremendous benefit, clinically and economically. In transplantation, the most important outcome measures are graft loss and patient mortality. Incidences of these outcome measures in SPKT are now reasonably low and have plateaued over the last 10 years [48] , making these poor comparators in clinical trials and routine clinical practice. Therefore, greater importance in assessing relevance of biomarkers in clinical practice should now be focused on the objective assessment of peri-operative morbidity, especially considering the prevalent nature of morbidity in our cohort [49] and the influence of peri-operative morbidity on long-term outcomes following major surgery [50] . POMS is an objective, validated assessment tool to evaluate patient morbidity following major surgery [51] and our data demonstrate that CRP at 48 h best correlates with a number of objective clinical outcome measures, including POMS on days 5, 7 and 10 (r = 0.461, 0.350 and 0.359 respectively) and the number of complications suffered by an individual as an inpatient (r = 0.394). It is interesting that a single and commonly available biomarker, CRP is statistically related to outcomes following SPKT in this study, but this finding is entirely consistent with studies in patients with acute pancreatitis [52] and pancreatic resections [53] .
We acknowledge limitations of this study in that the sample size is small, and the numbers of concomitant variables associated with outcomes in SPKT are large, limiting the analysis which could be performed. Therefore, to conduct a detailed multiple regression analysis, a larger cohort would need to be investigated. Nevertheless, in our analysis we have addressed the most clinically relevant variables affecting this cohort, with the aim of proposing factors affecting biomarker levels and the predictive capabilities of specific biomarkers to outcome post-SPKT. This study only begins to elucidate the inflammatory response to SPKT, modulated by the background of immunosuppression and clearly warrants further study, as our findings suggest this approach could have wide clinical implications for improved patient stratification and better outcome.
Our cohort was treated with two doses (30 mg each), of subcutaneous alemtuzumab, administered 24 h apart and a single dose of methylprednisolone at the time of anaesthetic induction. Glucocorticoids have been linked with reducing circulating pro-inflammatory cytokines [54] , whilst alemtuzumab is a monoclonal antibody which induces antibody mediated lysis of the cell. Therefore, with the conventional view of macrophages being an inflammatory cell, one would have expected to see a reduction in macrophage numbers, and consequently inflammatory cytokines, following immunosuppression induction. Conversely, the opposite was noted. This may be explained in two ways; first possibly due to the sub-cutaneous administration of alemtuzumab, therefore likely reducing overall absorption, compared to the intra-venous route [55] , which would explain the delayed antiinflammatory response and the persistently low IM levels measured 24 h onwards. However, alemtuzumab has also been reported to stimulate a type 1 hypersensitivity reaction that would increase circulating pro-inflammatory cytokines. Although clinical anaphylaxis is rare, the acute pro-inflammatory tendency may be contributing to the acute pro-inflammatory state observed. Therefore, perhaps a specific anti-inflammatory induction regimen would also negate the acute proinflammatory effects of alemtuzumab.
Second, in recognition of the growing importance of alternative macrophage polarization in disease, and the characteristics and phenotypic diversity macrophages that underlie the cells' actions, as well as the contribution of resident versus infiltrating macrophages/monocytes, and indeed, the role of macrophage mediators, a larger prospective study is needed to confirm our preliminary results, of a significantly increased presence of both M1 and M2 macrophages within the context of SPKD. Whether the surgical insult, or patient stratification affects macrophage phenotypic switch in the omental and/or other tissues, or whether outcome is determined by macrophage function, remains to be elucidated. These further studies could have a novel direction towards the potential of macrophages as a therapeutic target in SPKT and provide promising strategies to manage patients following transplantation.
